11.08.17
Cambrex Corp., a manufacturer of small molecule Active Pharmaceutical Ingredients (APIs), has completed an expansion of cGMP small scale capacity at its Charles City, IA plant.
The project included the installation of two 500-gallon glass lined reactors, and the creation of a third small scale work center, increasing flexibility for customer projects.
“Small scale manufacturing has been identified as being a crucial area where capacity is at a premium within the industry, and this investment has been undertaken to increase our flexibility and reduce potential project bottle necks to benefit our customers,” said Joe Nettleton, vice president U.S. Operations, Cambrex. “This continues Cambrex’s ongoing commitment to investing in small molecule manufacturing, ensuring that we can meet the challenges of customer project timelines, especially at the key development stages.”
The company also recently completed an expansion of large scale manufacturing capabilities and as well as a $24 million, 4,500 sq.-ft. highly potent API (HPAPI) manufacturing facility at Charles City, which is due to open in 2019.
The project included the installation of two 500-gallon glass lined reactors, and the creation of a third small scale work center, increasing flexibility for customer projects.
“Small scale manufacturing has been identified as being a crucial area where capacity is at a premium within the industry, and this investment has been undertaken to increase our flexibility and reduce potential project bottle necks to benefit our customers,” said Joe Nettleton, vice president U.S. Operations, Cambrex. “This continues Cambrex’s ongoing commitment to investing in small molecule manufacturing, ensuring that we can meet the challenges of customer project timelines, especially at the key development stages.”
The company also recently completed an expansion of large scale manufacturing capabilities and as well as a $24 million, 4,500 sq.-ft. highly potent API (HPAPI) manufacturing facility at Charles City, which is due to open in 2019.
